NCT00282282View on ClinicalTrials.gov

Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

January 31, 2009

Study Completion Date

July 31, 2009

Conditions
Graft Versus Host DiseaseGVHD
Interventions
DRUG

tacrolimus

Given orally just prior to and following stem cell transplant

DRUG

sirolimus

Given orally just prior to and following stem cell transplant

DRUG

fludarabine

Given once daily over 30 minutes for 4 days

DRUG

busulfex

Given intravenously over 3 hours for 4 days

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT00282282 - Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation | Biotech Hunter | Biotech Hunter